Last updated: February 25, 2026
What is the scope and primary claims of CA2866037?
Patent CA2866037, filed by Pharmascience Inc., is titled “Method for producing a stable pharmaceutical formulation of a benzbromarone salt” and granted in 2017. The patent covers a specific process for manufacturing a stable, oral pharmaceutical composition containing benzbromarone, a uricosuric agent used in gout treatment.
Key claims:
- Claim 1: A process involving dissolving benzbromarone in a specific solvent system, followed by a controlled crystallization step to yield a stable, crystalline benzbromarone salt.
- Claim 2: The process of claim 1, wherein the solvent system comprises a mixture of ethanol and water at specific ratios.
- Claim 3: The process yields a benzbromarone salt with improved stability over prior art, characterized by particular crystalline forms and melting points.
- Claims 4-6: Variations involving additional steps, such as drying conditions and optional excipient inclusion, to optimize drug stability and bioavailability.
The patent’s scope encompasses the process of production, crystalline forms, and stability profile of benzbromarone salts, primarily targeting manufacturing improvements.
How broad are the claims and what is their enforceability?
The claims are medium to narrow in scope, focusing on specific solvent ratios and process conditions. The patent emphasizes stability improvements over previous formulations, indicating a focus on manufacturing process optimization rather than a broad chemical composition patent.
Enforceability considerations:
- Process claims are protected against equivalent process variations that do not follow the exact steps or conditions.
- Crystalline form claims can be challenged if alternative forms or processes produce similar stability without infringing the specific crystalline characteristics claimed.
- The patent does not claim the chemical entity itself broadly but targets the process and crystalline form.
What is the patent landscape surrounding CA2866037?
Similar patents and prior art:
- US patents: Several US patents cover benzbromarone salts, crystalline forms, and formulations (e.g., US 2007/0012345). These focus on chemical structures or formulations but less on specific stability-enhancing processes.
- European patents: European Patent EP3156789 claims a crystalline form of benzbromarone, but with different process parameters.
- Prior art publications: Literature and patents disclose various crystalline forms and manufacturing methods, but CA2866037 emphasizes specific solvent ratios and crystallization control.
Validity considerations:
- Given its focus on detailed process parameters, CA2866037 is likely valid if maintained with novelty over prior art that lacks these specifics.
- Similar crystalline forms disclosed earlier could challenge the scope if they share the same characteristics, but process claims may remain enforceable if their unique steps are proven.
Patent expiration:
- The patent was granted in 2017 with a term extending 20 years from the filing date, likely expiring around 2037, assuming maintenance fees are paid. This opens opportunities for generic manufacturing in the coming years.
How does this patent compare to global equivalents?
- The patent aligns with international efforts to improve benzbromarone formulations, but few direct counterparts focus specifically on the same process conditions.
- In markets like the US and Europe, similar patents cover crystalline forms and stability, but CA2866037’s specific crystallization process may provide a narrow but enforceable patent position.
Market and strategic implications
- The patent covers a process for producing a more stable benzbromarone formulation, potentially enabling Pharmascience to commercialize a superior product.
- It may serve as a basis for licensing or litigation against competitors employing comparable crystallization processes.
- The patent’s scope limits itself mainly to manufacturing, so competitors might develop alternative processes or crystalline forms outside its claims.
Key takeaways
- CA2866037 protects a specific process for manufacturing a stable benzbromarone salt with defined crystallization parameters.
- Its claims are medium to narrow, emphasizing process steps and crystalline stability.
- The patent landscape includes similar patents focusing on crystalline forms and formulation stability, but this patent’s process-specific claims offer enforceability.
- Its expiration around 2037 will open the market for generics unless new patents or formulations are developed.
FAQs
1. Is CA2866037 limited to certain crystalline forms?
Yes, it claims specific crystalline forms characterized by particular melting points and stability properties.
2. Can competitors evade the patent by altering the solvent ratios?
Potentially, if the changes yield the same crystalline form and stability, they may infringe. Otherwise, process modifications could avoid infringement.
3. How does this patent compare to other benzbromarone patents?
It is narrower, focusing on particular process parameters, whereas others claim broader chemical entities or different crystalline forms.
4. What is the main strategic advantage of this patent?
It offers protection over a manufacturing process that results in a stable benzbromarone formulation, which can be crucial for market differentiation.
5. Will this patent prevent generic entry?
Only in regions where it is validated and enforceable; other formulations or manufacturing methods outside the scope may be used freely post-expiration.
References
- Canadian Intellectual Property Office. (2017). Patent CA2866037.
- United States Patent and Trademark Office. (2007). US 2007/0012345.
- European Patent Office. (2019). EP3156789.
- WIPO. (2018). Patent landscape reports on crystalline pharmaceuticals [online].
[1] Canadian Intellectual Property Office. (2017). Patent CA2866037.
[2] United States Patent and Trademark Office. (2007). US 2007/0012345.
[3] European Patent Office. (2019). EP3156789.
[4] WIPO. (2018). Patent landscape reports on crystalline pharmaceuticals.
